Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Caleb Youngblood

Physician Assistant, Medical Berkley, MI Physician Assistant

NPI 1235366014 CMS profile 10902352

1964 W 11 Mile Rd, Berkley, MI 48072

Open in the dashboard

General payments

$215,491

1,399 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Caleb Youngblood of Berkley, MI is reported in the CMS Open Payments database as having received $215,491 across 1,399 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $78,806 253
2024 General $45,629 313
2023 General $38,466 285
2022 General $26,143 242
2021 General $26,449 306

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Caleb Youngblood
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Caleb Youngblood were reported at $78,806. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Caleb Youngblood Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $26,449 $156 $41–$563 $132
2022 $26,143 $185 $55–$649 $149
2023 $38,466 $199 $58–$717 $160
2024 $45,629 $206 $62–$740 $164
2025 $78,806 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Gilead Sciences, Inc. $144,777 552 payments
  2. ViiV Healthcare Company $55,342 340 payments
  3. Theratechnologies Inc. $3,190 22 payments
  4. Merck Sharp & Dohme Corporation $2,459 45 payments
  5. Janssen Scientific Affairs, LLC $1,160 1 payment
  6. Janssen Biotech, Inc. $1,080 58 payments
  7. Janssen Products, LP $1,055 4 payments
  8. AbbVie, Inc. $935 55 payments
  9. Novo Nordisk Inc $589 41 payments
  10. AstraZeneca Pharmaceuticals LP $444 26 payments
  11. Other $4,460 255 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $138,783 107 payments
  2. Travel and Lodging $36,797 100 payments
  3. Food and Beverage $27,364 1,171 payments
  4. Consulting Fee $12,290 12 payments
  5. Education $258 9 payments
Products named General payments · program years 2021–2025
  1. Descovy $40,522 85 payments
  2. DOVATO $33,514 174 payments
  3. Biktarvy $32,261 57 payments
  4. Yeztugo $27,726 41 payments
  5. APRETUDE $19,294 82 payments
  6. Sunlenca $3,629 8 payments
  7. SYMTUZA $3,295 63 payments
  8. CABENUVA $2,127 59 payments
  9. PIFELTRO $2,076 26 payments
  10. EGRIFTA $1,190 20 payments
  11. Other $11,233 631 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 97 drugs

Part D claims

4,379

Median for Physician Assistant: 241

Drug cost

$3,092,004

Median for Physician Assistant: $4,110

Branded share of claims

37.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 272 $1,069,714
Symtuza Darunavir/Cob/Emtri/Tenof Alaf Brand 60 $334,161
Odefsey Emtricitab/Rilpiviri/Tenof Ala Brand 67 $233,911
Descovy Emtricitabine/Tenofov Alafenam Brand 100 $218,014
Dovato Dolutegravir Sodium/Lamivudine Brand 66 $208,056
Pifeltro Doravirine Brand 83 $162,568
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 33 $142,351
Jardiance Empagliflozin Brand 86 $119,604
Tivicay Dolutegravir Sodium Brand 35 $88,416
Juluca Dolutegravir/Rilpivirine Brand 19 $70,655

The 10 drugs with the highest cost, of 97 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$5,510

Medicare's payments for the services billed

Medicare patients

21

Average age 65

Services billed

149

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 57%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 45 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Biktarvy
$12,999 272 —
Descovy
$10,896 100 —
DOVATO
$7,920 66 —
APRETUDE
$1,813 — —
Sunlenca
$1,268 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 45 with Patron

Records

1,399 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record